RMTG Subsidiary Opens Advanced Cell Therapy Manufacturing Facility in Mexico
核心洞察
Regenerative Medical Technologies Group (搜索)'s subsidiary Cellgenic (搜索) will host a soft opening of its COFEPRIS (搜索)-licensed cell therapy manufacturing facility in Cancun, Mexico during September 2025.
The facility will produce investigational and regulated cell-based therapies including mesenchymal stem cells (搜索), exosomes (搜索), and natural killer cells (搜索) for orthopedics (搜索), neurology (搜索), pain management (搜索), and aesthetic medicine applications.
Full-scale operations are expected by January 2026, adding manufacturing revenue streams to RMTG's existing affiliate network spanning over 30 countries.
Regenerative Medical Technologies Group (搜索), Inc. (OTC:RMTG) announced that its subsidiary Cellgenic (搜索) will host the soft opening of its advanced cell therapy manufacturing facility in Cancun, Mexico during September 2025. The opening will coincide with the 2025 ISSCA Regenerative Medicine Global Summit, organized by the International Society for Stem Cell Application (搜索) (ISSCA), RMTG's educational and scientific division through its Global Stem Cells Group (搜索) subsidiary.
Strategic Manufacturing Infrastructure
The soft opening represents a significant milestone in RMTG's international expansion strategy, with plans to establish specialized infrastructure designed for the controlled manufacture, preservation, and distribution of human cellular products. The strategically located Cancun facility will support production of investigational and regulated cell-based therapies, including mesenchymal stem cells (搜索) (MSCs), exosomes (搜索), natural killer (NK) cells, and other biologics for orthopedics (搜索), neurology (搜索), pain management (搜索), aesthetic medicine, and longevity-focused therapies.
Regulatory Compliance and Operational Standards
The laboratory has received full licensing from COFEPRIS (搜索), Mexico's federal health authority, to operate as both a Stem Cell Collection Center and Stem Cell Bank. The facility features ISO-classified cleanrooms, cryopreservation systems, GMP-aligned workflows, and digital batch traceability systems to meet international standards.
Full-scale operations are expected by January 2026, which will add manufacturing revenue streams to RMTG's existing affiliate network spanning more than 30 countries. The facility also includes designated areas for physician education programs through the ISSCA platform, creating additional certification and training revenue opportunities.
"This laboratory represents a pivotal step in our expansion strategy," said David Christensen, CEO of RMTG. "We believe it provides a foundation for scientific growth, and we are optimistic about its potential to support regulated, high-quality cell-based technologies for physicians and institutions worldwide."
Market Opportunity and Global Reach
The soft opening is expected to attract more than 200 physicians, scientists, and biotech leaders from over 30 countries attending the ISSCA Global Summit. The facility tour will provide attendees with an opportunity to observe manufacturing systems and quality safeguards, demonstrating RMTG's commitment to compliance and scientific rigor in the rapidly expanding regenerative medicine market.
"Our intention with this laboratory is to strengthen the infrastructure needed for responsible and scalable regenerative medicine," said Benito Novas, Founder of Global Stem Cells Group (搜索). "With the COFEPRIS (搜索) authorizations in place, we believe this facility will serve as a strategic base to support the production and distribution of therapies that meet rigorous safety and quality expectations."
Financial Impact and Revenue Projections
The company reported Q1 2025 sales of $1.35 million representing 67% growth with operational profits of $134,000. The Cancun facility operates under Mexico's legal and biosafety framework for cellular product collection, processing, storage, and release. Full manufacturing operations beginning January 2026 will complement RMTG's existing revenue model and support the company's decentralized production strategy for faster, cost-effective delivery while helping partners navigate regulatory processes.
The laboratory will serve as a center for ongoing research, clinical collaboration, and physician education through ISSCA training programs. These programs support healthcare professionals in developing expertise with cell-based protocols while maintaining emphasis on ethics, compliance, and patient safety.